Theragenics(R) Renews Credit Agreement

Available Borrowings Increased to $40 Million Under Amended and Restated Credit Agreement

BUFORD, Ga.--(BUSINESS WIRE)-- Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has entered into a Second Amended and Restated Credit Agreement with Wells Fargo Bank, National Association. The new three year credit agreement, which is unsecured, replaces the $30 million credit agreement with Wells Fargo that was set to expire on October 31, 2012. Borrowings of $22 million that were outstanding under the old credit agreement have been refinanced under the new $40 million credit agreement. The interest rate on outstanding borrowings under the new credit agreement has been reduced from LIBOR plus 2.25% to LIBOR plus 1.75%. The financial covenants in the new credit agreement are substantially similar to the previous credit agreement.

“Obtaining our new credit agreement is a significant accomplishment,” stated M. Christine Jacobs, Chairman and Chief Executive Officer of Theragenics. “We believe that the increase in the available credit and the lower interest rate, in the current credit environment, is attributable to our strategy, our focus on cash flows and the strength of our balance sheet. With this new credit agreement in place we can continue to focus on our strategy of growth and diversification.”

Under the new amended and restated credit agreement, the $40 million revolving line of credit matures on October 10, 2015, with interest payable at LIBOR plus 1.75%. $22 million in revolving loans are currently outstanding under this revolving line of credit. The new credit agreement is unsecured but provides for a lien to be established on substantially all assets of the Company if certain events of default occur. Provisions of the new credit facility require the Company to maintain a minimum cash and investment balance, as defined in the agreement, of $10 million. The terms also require the maintenance of certain minimum financial covenants, including a minimum fixed charge coverage ratio and a maximum debt to tangible net worth.

Theragenics Corporation (NYSE: TGX) operates two business segments: its surgical products business and its brachytherapy seed business. The surgical products business (www.cpmedical.com, www.galtmedical.com, www.needletech.com) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, RF devices, implanters, introducer products and other needle-based products. The surgical products segment serves a number of markets and applications, including, among other areas, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. Theragenics’ brachytherapy business manufactures, markets and distributes “seeds” used primarily in the minimally invasive treatment of localized prostate cancer. The Company’s brachytherapy product line includes its palladium-103 TheraSeed^® device and its iodine-125 AgX100™ device (www.theragenicsbrachy.com). The terms "Company," "we," "us," or "our" mean Theragenics Corporation and all entities included in our consolidated financial statements. For additional information, call our Investor Relations Department at [phone] or visit www.theragenics.com.

Theragenics Corporation
Frank Tarallo, 800-998-8479 or 770-271-0233
CFO and Treasurer
or
Lisa Rassel, 800-998-8479 or 770-271-0233
Manager of Investor Relations
[e-mail]

Source: Theragenics Corporation